MD Anderson and AmMax Bio Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

MD Anderson and AmMax Bio announced agreements to develop and advance AmMax’s AMB-066 monoclonal antibody therapy for colorectal cancer with minimal residual disease. 

Read More